Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

Subjects will all participate in a 6-month weight loss intervention. Subjects will be randomized to receive either blinded placebo or omega-3 fatty acids for 6 months.

Inclusion criteria

• Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial cells on cytology slide of screening Random Periareolar Fine Needle Aspiration (RPFNA)
• Access to smart phone and or computer
• Willing to comply with diet, exercise and lifestyle modification during weight reduction and maintenance phase.
• Willing to start the dietary and exercise intervention within 9 months of RPFNA
• Willing to complete quality of life questionnaires at multiple visits
• Willing to have a medical history and physical at multiple visits
• Willing to have an additional RPFNA at two additional visits
• Be willing to have blood drawn at multiple visits
• Willing to sign and able to understand consent for the RPFNA's and study participation
• Reasonable hematopoetic, kidney and liver function consistent with safe participation on this trial.

Exclusion criteria

• Having taken medications that seriously affect metabolism such as steroids, dexatrim or other diet drugs within 3 weeks of study registration
• Have changed dose or type of hormone supplementation within 3 months
• Currently receiving other investigational agents
• Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen Receptor Modulator or aromatase inhibitor within last 6 months.
• Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other anti-inflammatory agents
• Taking metformin, or other diabetes medications
• Taking statins
• Unable to participate in moderate intensity exercise (walking, treadmill, elliptical, water aerobics)
• Would be unable to participate, by phone, in weekly phone call sessions
• Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist.